Testicular cancer and sperm DNA damage: short- and long-term effects of antineoplastic treatment

Area of Science:

• Reproductive Medicine
• Oncology
• Genetics

Background:

• Testicular cancer treatments, including chemotherapy and radiotherapy, can impact sperm DNA integrity.
• Assessing sperm DNA damage is crucial for understanding male reproductive potential after cancer therapy.

Purpose of the Study:

• To investigate sperm DNA damage (DFI) induced by chemo- and radiotherapy in testicular cancer patients.
• To determine the extent and persistence of nuclear DNA damage affecting reproductive potential.
• To correlate DNA damage with treatment type, intensity, and cancer stage.

Main Methods:

• Sperm DNA fragmentation index (DFI) was evaluated using sperm chromatin structure assay.
• Measurements were taken pre-treatment (T0) and at multiple time points post-treatment (T3, T6, T12, T24 months).
• Data were analyzed in relation to treatment type (chemotherapy vs. radiotherapy) and cancer stage.

Main Results:

• Mean DFI was 18.0% at baseline, increasing significantly at 3 and 6 months post-treatment (T3: 27.7%, T6: 23.2%).
• DFI improved considerably by 12 and 24 months (T12: 14.0%, T24: 14.4%), nearing baseline levels.
• Chemotherapy showed a more pronounced DFI increase and subsequent recovery compared to radiotherapy.
• Advanced cancer stage and treatment intensity correlated with greater post-treatment DNA damage.

Conclusions:

• Sperm DNA damage is evident in the months following testicular cancer treatment.
• DNA integrity generally recovers within 12-24 months, but the pattern varies by therapy.
• The degree of DNA damage is influenced by treatment modality, intensity, and the pathological/clinical stage of the cancer.